Compare STEL & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEL | NNNN |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2025 |
| Metric | STEL | NNNN |
|---|---|---|
| Price | $30.73 | $29.48 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $31.33 | N/A |
| AVG Volume (30 Days) | ★ 266.7K | 37.2K |
| Earning Date | 01-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.94 | 0.06 |
| Revenue | ★ $416,539,000.00 | $6,920,153.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.41 | N/A |
| P/E Ratio | ★ $15.86 | $502.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.13 | $5.18 |
| 52 Week High | $32.74 | $55.65 |
| Indicator | STEL | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 47.83 |
| Support Level | $31.16 | $31.18 |
| Resistance Level | $31.14 | $38.00 |
| Average True Range (ATR) | 0.60 | 3.72 |
| MACD | -0.19 | -0.50 |
| Stochastic Oscillator | 10.80 | 28.64 |
Stellar Bancorp Inc is a U.S. based bank holding company. Through its subsidiary, Stellar Bank, the company provides a diversified range of commercial banking services predominantly to small to medium sized businesses, professionals, and individual customers. Its offerings include different types of loans, such as mortgage loans, home equity loans, automobile loans, etc.; deposit products, such as checking accounts, commercial accounts, money market accounts, savings accounts, etc.; and other banking services like mobile banking, debit cards, cash management and wire transfer services, letters of credit, and others.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.